Log In
Print this Print this

NaBen (SND13)

  Manage Alerts
Collapse Summary General Information
Company SyneuRx International Taiwan Corp.
DescriptionSodium benzoate, a D-amino-acid oxidase (DAO) (DAAO) inhibitor
Molecular Target D-amino-acid oxidase (DAO) (DAAO)
Mechanism of Action 
Therapeutic Modality 
Latest Stage of DevelopmentPhase II/III
Standard IndicationSchizophrenia
Indication DetailsTreat schizophrenia as adjunctive therapy; Treat schizophrenia in adolescents as adjunctive therapy
Regulatory Designation U.S. - Breakthrough Therapy (Treat schizophrenia as adjunctive therapy)

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today